A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-10-28
Adverse events
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 54); relationship: N
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 91); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-04-05 (study day 145); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 273); relationship: N
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-09 (study day 302); relationship: not assessed
Data queries
No data queries.